硫酸氢氯吡格雷联合西洛他唑治疗糖尿病四肢并发症的临床疗效观察
摘要
Objective: To observe efficacy and safety of domestic clopidogrel cilostazol in treatment of diabetic limbs complications. Methods: 120 cases of diabetic patients with limb complications were randomly selected, including 60 cases of lower extremity arterial disease (PAD) and 60 patients with diabetic peripheral neuropathy (DPN) patients. According to the random number list, they were randomly divided into treatment group of 60 patients, DPN and PAD were given mecobalamin 0. 5mg / times , lipoic acid 500mg / d, alprostadil 10ug / d, DPN patients while giving epalrestat 50mg / times. The control group while giving cilostazol 0.1g, 2 times / d, plus clopidogrel treatment groups 150mg / d in the control group, based on continuous treatment for 8 weeks. Clinical evaluation of the two groups was made and conduction velocity of MNCV and SNCV was compared. R esults: Analysis of DPN subgroup showed that the treatment group was efficient (73.4% vs 46.7%, P = 0.035), total efficiency (93.3% vs 73.3%, P = 0.038) were significantly higher, PAD subgroup analysis showed the efficiency of the treatment group was (70% vs 43.3%, P = 0.035), total efficiency (93.3% vs 73.3%, P = 0.038) were significantly higher. MNCV CKS nerve (54.3 ± 4.8 vs 50.5 ± 5.1) and the peroneal nerve (34.7 ± 3.2 vs 30.9 ± 3.4) conduction velocity improved more significantly. SNCV CKS nerve (43.4 ± 4.9 vs 38.2 ± 3.8) and the peroneal nerve (35.1 ± 5.6 vs 32.9 ± 5.4) conduction velocity, the treatment group improved significantly than the control group. PAD subgroup analysis, ABI degree of improvement (0.9 ± 0.3 vs 0.8 ± 0.3), dorsal blood flow (35.2±3.6 vs31.5±4.2), popliteal artery blood flow (64.2±5.6 vs 58.4±7.4) were better than the control group. Compared with clopidogrel, cilostazol did not increase in adverse events during treatment process. Conclusion : Clopidogrel cilostazol treatment of diabetic limb complications becomes safe and effective treatment of DPN and PAD, which can be used as a combination